Today: Today, 5,000 Shares of Stock are sold by Insider Selling: Entellus Medical Inc. (ENTL) Director

Today, 5,000 Shares of Stock are sold by Insider Selling: Entellus Medical Inc. (ENTL) Director

Entellus Medical Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 23rd. The shares were sold at an average price of $19.00, for a total value of $95,000.00. Following the transaction, the director now owns 494,581 shares in the company, valued at $9,397,039. The sale was disclosed in a document filed with the SEC, which is available at this link.

Entellus Medical Inc. (NASDAQ:ENTL) traded down 0.94% during midday trading on Monday, hitting $18.99. The stock had a trading volume of 32,476 shares. Entellus Medical Inc. has a 52 week low of $13.72 and a 52 week high of $22.63. The firm has a 50 day moving average of $19.12 and a 200 day moving average of $18.64. The firm’s market cap is $358.23 million.

Entellus Medical (NASDAQ:ENTL) last announced its earnings results on Thursday, November 3rd. The medical technology company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.13. The business had revenue of $17.90 million for the quarter, compared to the consensus estimate of $17.93 million. Entellus Medical had a negative net margin of 36.91% and a negative return on equity of 53.20%. Entellus Medical’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.32) EPS. Equities research analysts predict that Entellus Medical Inc. will post ($1.42) EPS for the current year.

ENTL has been the topic of several recent analyst reports. Canaccord Genuity restated a “buy” rating and set a $23.00 price objective on shares of Entellus Medical in a research note on Friday, August 5th. BTIG Research restated a “buy” rating and set a $22.00 price objective on shares of Entellus Medical in a research note on Friday, August 5th. Zacks Investment Research upgraded Entellus Medical from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Monday, August 8th. Finally, Deutsche Bank AG initiated coverage on Entellus Medical in a research note on Thursday, October 6th. They set a “buy” rating and a $26.00 price objective on the stock. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $22.75.

Institutional investors have recently made changes to their positions in the stock. Murphy Michael R increased its position in shares of Entellus Medical by 30.1% in the second quarter. Murphy Michael R now owns 627,441 shares of the medical technology company’s stock worth $11,463,000 after buying an additional 145,304 shares in the last quarter. Cortina Asset Management LLC boosted its stake in shares of Entellus Medical by 39.2% in the second quarter. Cortina Asset Management LLC now owns 421,897 shares of the medical technology company’s stock valued at $7,708,000 after buying an additional 118,745 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Entellus Medical by 40.1% in the second quarter. BlackRock Fund Advisors now owns 195,518 shares of the medical technology company’s stock valued at $3,572,000 after buying an additional 55,996 shares during the last quarter. State Street Corp boosted its stake in shares of Entellus Medical by 89.2% in the second quarter. State Street Corp now owns 96,040 shares of the medical technology company’s stock valued at $1,753,000 after buying an additional 45,267 shares during the last quarter. Finally, Perkins Capital Management Inc. boosted its stake in shares of Entellus Medical by 119.8% in the third quarter. Perkins Capital Management Inc. now owns 49,450 shares of the medical technology company’s stock valued at $1,097,000 after buying an additional 26,950 shares during the last quarter. Institutional investors own 71.55% of the company’s stock.

Entellus Medical Company Profile

Related posts

Leave a Comment